letrozole as ovulation inducer
Post on 22-Jan-2018
66 Views
Preview:
TRANSCRIPT
Letrozole in Ovulation Induction
1
Dr Sujoy DasguptaMBBS (Gold Medalist, Hons)
MS (Obst & Gynae- Gold Medalist)DNB, FIAOG
Fellow- reproductive Endocrinology and Infertility (ACOG, USA)
Assistant Professor: SRIMSH, Durgapur
Consultant: RSV Hospital, KolkataBehala Balananda Brahmachary Hospital, KolkataTechno India Hospital, Kolkata
Secretary, Perinatology Committee: Bengal Obstetric and Gynaecological Society (BOGS)- 2016-17Managing Committee Member: BOGS- 2016-17East Zone Representative, FOGSI Youth Cell (FOGSI Future) 2017-18
15 Publications: National and International Journals
NoticeMedicine is an ever-changing science. As new research and clinical
experience broaden our knowledge, changes in treatment and drug
therapy are required. The authors and the publisher of this work have
checked with sources believed to be reliable in their efforts to provide
information that is complete and generally in accord with the standards
accepted at the time of publication. However, in view of the possibility of
human error or changes in medical sciences, neither the authors nor the
publisher nor any other party who has been involved in the preparation or
publication of this work warrants that the information contained herein is in
every respect accurate or complete, and they disclaim all responsibility for any
errors or omissions or for the results obtained from use of the information
contained in this work. Readers are encouraged to confirm the information
contained herein with other sources.
2
5
Incidence of all malformations was not different betweenthe two groups (p= 0.25, 95%CI 0.78-4.71). However, the incidence of locomotor malformations (p= 0.0005, 95% CI 2.64-27.0) and cardiac anomalies (p= 0.0006 95% CI 3.30-58.1) were higher than in the control groups
6
Fertil Steril. 2006 Jun;85(6):1761-5
No difference in overall rates of major & minor congenital malformationsamong newborns from mothers who conceived after LTZ or CC treatments
It appears that congenital cardiac anomalies are less frequent in LTZ group
The concern that LTZ use for ovulation induction could be teratogenic isunfounded based on this data
LTZ stimulation
Reduces risk of miscarriage
No increase in risk of
Major congenital anomalies
Adverse pregnancy outcomes
Adverse neonatal outcomes
Conclusions
11
Safer option for mild ovarian stimulation
Sharma S, et al. PLoS ONE. 2014; 9(10): e108219
12
Structural malformations &
chromosomal abnormalities
Natural conception group
5 / 171 babies
(2.9%)
LTZ group5 / 201 babies
(2.5%)
CC group10 / 251 babies
(3.9%)
Other StudiesReference No of patients
Forman R, et al. J Obstet Gynaecol Can 2007;29:668-71. 430
Dehbashi S, et al. Iran J Med Sci 2009;34:23-8. 100
Legro RS, et al. N Engl J Med. 2014 Jul 10;371(2):119-29. 750
Banerjee Ray P, et al. Arch Gynecol Obstet. 2012 Mar;285(3):873-7. 147
Roy KK, et al. J Hum Reprod Sci. 2012 Jan-Apr; 5(1): 20–25 204
Wu XK, et al. Fertil Steril 2016;106:757-765 644
Requena A, et al. Hum Reprod Update. 2008 Nov-Dec;14(6):571-82.
(Meta-analysis)
2573
Diamond MP, et al. N Engl J Med 2015;373:1230-40. 900
Causes of Subfertility
Ovulatory
20%
Male Factor
30%Tubal
25%
Unexplained
25%
18
NICE Guidelines. Fertility Problems: Assessment and Treatment
nice.org.uk/guidance/cg156
WHO Classification of Anovulation
E2 FSH Cause %
Type I ↓ ↓ Hypothalamo-Pituitary
Failure
1-2
Type II ↑/
Norm
al
Normal,
high LH
Hypothalamo-Pituitary
Dysfucntion
(Predominantly PCOS)
>90
Type III ↓ ↑ Ovarian Failure 10
19
granulosa cells
FSH
aromatase
LH
theca cells
androstenedioneestrogen
20
Follicular Physiology
Aromatase
Exogenous FSH
CC binds to ER & depletes
receptor concentrations
aromatase inhibition
Management of PCOS-Anovulation
Life Style Modification
CC
1st Line Treatment
No Ovulation (CC Resistance)
Metformin + CC FSH Lap Ovarian Drilling Letrozole
Ovulates
21
Management of PCOS-Anovulation
Life Style Modification
CC
1st Line Treatment
No Ovulation (CC Resistance)
Metformin + CC FSH Lap Ovarian Drilling Letrozole
Ovulates
22
1st line treatment for OI for >55 yrs
Ovulation: 60-85% cases
About 20-25% of anovulatory women are CC-resistant
Pregnancy rate: 10-20%/cycle
Failure of 6 CC cycles: Other factors for infertility should be considered
Effective & safe oral agent
Thins out endometrium, reduces cervical secretion
23
Clomiphene Citrate
Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.; Banerjee Ray P, et al. Arch Gynecol Obstet. 2012 Mar;285(3):873-7.;
Pavone ME, et al. J Clin Endocrinol Metab. 2013 May; 98(5): 1838–1844.
Letrozole
• 3rd generation aromatase inhibitor (AI)
• Non-steroidal, potent & selective
• 1st study (Mitwally & Casper, 2001): OI
24Mitwally MF, et al. Fertil Steril. 2001 Feb;75(2):305-9.
Endometrial thickness & E2 levels
In anovulatory patients with PCOS
Variable LTZ treatment CC treatment P value
ET (mm) 8.1 ± 1.4 6.2 ± 2.5 <0.01
E2 levels on day of hCG
(pmol/L)
962 ± 654 1638 ± 1406 <0.01
In ovulatory patients
Variable LTZ treatment CC treatment P value
ET (mm) 8.9 ± 1.2 5.0 ± 1.0 <0.001
E2 levels on day of hCG
(pmol/L)
719 ± 411 3003 ± 1422 <0.001
26
Letrozole vs CC
Legro RS, et al. N Engl J Med. 2014
Jul 10;371(2):119-29.
Ovulation, Pregnancy, and Live
Birth rates- all were significantly
better in Letrozole group, in women
with normal and with high BMI
Banerjee Ray P, et al. Arch Gynecol
Obstet. 2012 Mar;285(3):873
Pregnancy rate and Live birth rates
were better in letrozole group
Roy KK, et al. J Hum Reprod Sci.
2012 Jan-Apr; 5(1): 20–25.
Miscarriage rates were similar than
CC
Multiple pregnancy rates higher
with CC
Letrozole may be considered as the
1st line of agent for OI28
-7.
Secondary outcomes: Others
No statistically significant difference
between LTZ & CC groups in…Ovulation rate per cycle
▪ RR=1.15; 95% CI: 0.98–1.34
Multiple pregnancy rates▪ RR=0.43; 95% CI: 0.17–1.06
Miscarriage rate▪ RR=1.43; 95% CI: 0.98–2.06
Letrozole vs. LOD in CC Failure
LTZ had superior reproductive outcomes compared with LOD in women with CC-resistant PCOS
LTZ could be used as 1st line treatment for women with CC-resistant PCOS
Liu W, et al. Experimental and Therapeutic Medicine. 2015; 10: 1297-1302.
35
Comparison of Letrozole vs. Tamoxifen
LTZ superior to TMX
Higher pregnancy
rate
Higher ovulation
rate
El-Gharib et al. J Reprod Infertil. 2015; 16(1): 30-35.
36
Letrozole plus Gn in CC-resistant
infertile women with PCOS
Xi W, et al. Drug Des Devel Ther. 2015; 9: 6001–6008.
37
Conclusion
LTZ in combination with
HMG
Reduce risks of OHSS in CC-resistant women with PCOS
More appropriate in patients sensitive to gonadotropin
38
GuidelinesSociety Year Recommendation
ACOG 2016 Letrozole- 1st-line therapy for PCOS &
BMI > 30
WHO 2016 CC or Letrozole
Australian National Health and
Medical Research Council
(NHMRC) guideline
2015 CC or Letrozole
American Association of
Clinical Endocrinologists,
American College of
Endocrinology,
Androgen Excess and PCOS
Society
2015 CC or Letrozole
Endocrine Society 2013 CC or Letrozole
39
Prescribing information; Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771; Harriet et al. Drugs 1998; 56(6):1125-1140;Bhatnagar AS. Breast Cancer Res Treat 2007;105:7–17
Pharmacology
40
Parameter Data
Absorption Rapid & complete (Cmax within 1 h)
Bioavailability 99.9%
Food Absorption not affected by food
Metabolism Inactive metabolite, by CYP 2A6 & 3A4
Elimination T1/2 ~2 days (45 h)
Excretion Renal (90%), rapid clearance, no accumulation
Safety Well tolerated
Dose, Duration, Monitoring
Ovulation
Menses
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 … 28
LTZ 2.5 mg/d
hCG 10,000 IU IM
(follicle ≥18 mm/; ET > 7 mm)
Timed intercourse/ IUI
24-36 h after hCG
administration
41
Dose >2.5 mg/ d andmore than 3 cycles is not recommended
TVS Monitoring
TVS Monitoring is recommended at least in 1st cycle
Advantages of letrozole over CC
Parameters Clomiphene citrate Letrozole
MOA SERM Aromatase inhibitor
Half-life Long, 5-7 days Short, 45 h
Anti-estrogenic
effects
Thin endometrium & altered
cervical mucus
Thick endometrium &
favourable cervical
mucus
Uterine blood flow Decreased Increased
OHSS risk High Low
Multiple pregnancy High Low
42
Casper RF, et al. J Clin Endocrinol Metab. 2006; 91: 760-771.
Summary
43
Better pregnancy outcomes & higher live births compared to CC in PCOS patients
Effective even in patients with CC-resistant PCOS
Reduces Gn dose & superior alternative to CC in combined Gn cycles
Monofollicular development & lower multiple pregnancies
No anti-estrogenic effects on endometrium & cervical mucus
Lower cycle cancellation & risk of hyperstimulation
Safety established in clinical studies
top related